Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
174.91
-1.58 (-0.90%)
At close: Jul 11, 2025, 4:00 PM
174.96
+0.05 (0.03%)
After-hours: Jul 11, 2025, 5:23 PM EDT
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 17 analysts that cover Ascendis Pharma stock have a consensus rating of "Strong Buy" and an average price target of $222.18, which forecasts a 27.03% increase in the stock price over the next year. The lowest target is $153 and the highest is $289.
Price Target: $222.18 (+27.03%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 6 | 6 | 7 | 9 | 9 | 10 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 15 | 16 | 16 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $213 → $243 | Strong Buy | Maintains | $213 → $243 | +38.93% | Jul 11, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $250 | Buy | Initiates | $250 | +42.93% | Jul 3, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $215 → $224 | Buy | Maintains | $215 → $224 | +28.07% | Jun 13, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $201 → $216 | Strong Buy | Maintains | $201 → $216 | +23.49% | Jun 9, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $196 → $201 | Strong Buy | Maintains | $196 → $201 | +14.92% | Jun 3, 2025 |
Financial Forecast
Revenue This Year
644.34M
from 363.64M
Increased by 77.19%
Revenue Next Year
1.13B
from 644.34M
Increased by 75.84%
EPS This Year
-4.20
from -6.53
EPS Next Year
1.20
from -4.20
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 842.1M | 1.6B | 2.6B | ||
| Avg | 644.3M | 1.1B | 1.7B | ||
| Low | 500.4M | 836.1M | 1.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 131.6% | 154.5% | 127.4% | ||
| Avg | 77.2% | 75.8% | 53.9% | ||
| Low | 37.6% | 29.8% | 11.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.91 | 6.06 | 12.57 | ||
| Avg | -4.20 | 1.20 | 7.30 | ||
| Low | -7.53 | -3.05 | 1.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 950.0% | ||
| Avg | - | - | 510.1% | ||
| Low | - | - | 66.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.